406
Participants
Start Date
June 23, 2023
Primary Completion Date
September 23, 2025
Study Completion Date
September 23, 2026
Dalbavancin administration
"A single-dose of intraveneuse (IV) administration of dalbavancin of 1500 mg.~In case of patients with chronic renal impairment (creatinin clairance \< 30mL/min), a single-dose of IV administration of reduced dalbavancin of 1000 mg."
Standard antibiotic therapy
Standard Antibiotic therapy according to national recommendations. During the study, the start of treatment is considered to be the day of inclusion/randomization (even if active antiobiotic treatment was started, less than 72 hours ago according to inclusion criteria).
RECRUITING
Infectious Diseases Department, CH PERIGUEUX, Périgueux
NOT_YET_RECRUITING
Infectious Diseases Department, Raymond-Poincaré Hospital - APHP, Garches
Collaborators (1)
Centre Hospitalier de Perigueux
OTHER
Advanz Pharma
INDUSTRY
Nantes University Hospital
OTHER
Centre National de Référence des staphylocoques
UNKNOWN
Assistance Publique - Hôpitaux de Paris
OTHER